Our Technology

Rapid AST: Find the right treatment

Once the pathogen is known, the next step is to identify the treatment. Currently, physicians are often limited to starting patients on the most likely antibiotic before complete laboratory tests can confirm which treatment will work. This process requires full laboratory equipment and 3-4 days.

GeneCapture is developing a method that uses the sample provided to test a range of different antibiotics and identifies which treatment will work in 90 minutes. This method is still in testing, and it is showing strong early results.

Rapid ID: Identify the pathogen

Starting with a urine, swab, or blood sample, GeneCapture can can identify the pathogen in 90 minutes. This portable platform does requires no refrigeration, no laboratory, and no special medical training.

The cartridge, which is the heart of the platform, has a large library of pathogen probes. We can test for more than 200 pathogens, and we’re developing more now. Also, we can test for Pathogen X, meaning that if there is a new pandemic or biothreat, we can design and deploy a probe quickly. We’re proud to partner with the military to prepare for future threats.

The probes are based on the sequence of the pathogen, so they are highly specific and sensitive. Other groups have tested our bur-drug pairs and validated our methods. We’re looking forward to our FDA clinical tests.

How does the CAPTURE Platform work?

Confirming Active Pathogens Through Unamplified RNA Expression, technology is built to function independently of a lab. CAPTURE can test for hundreds of pathogens in under one hour and can deliver an antibiotic sensitivity report in an additional two hours.

Over 5000 tests have been run in our lab to develop this technique which is designed to deliver 98% specificity and 98% sensitivity. After identification, an Antibiotic Susceptibility Test can be accomplished with a second cartridge using growth media and periodic pathogen counts in controlled or antibiotic wells.

This video shows how the CAPTURE Platform identifies pathogens through their RNA.

The magic is in the cartridge

The raw urine, blood or swab sample is inserted directly into the universal, disposable CAPTURE cartridge, which is engineered such that the RNA is extracted directly from the sample.

A microarray of germ-matching probes identify the pathogen. The inset of green dots is an image taken with GeneCapture equipment of the microarray results. The pattern reveals which pathogen is present.

Overview of our technology workflows

Product Status

  • We have an operating prototype and manufacturable-quality cartridge that is patented and developed.

  • In 2025, we received FDA Study Concurrence for our first go-to-market product: a Urinary Tract Infection test. FDA study concurrence means that our working prototype is projected by our regulatory team to have a 98% success rate in FDA clinical trials. We plan to apply for FDA clinical trials in August of 2027.

  • Our Rapid Antibiotic Susceptibility Test was validated (#####)

  • Probes designed for 30 unique pathogens

  • 8 patents and trade secrets